4-(3-Methyl-pyridin-2-yl)-[1,4]diazepane-1-carboxylic acid tert-butyl ester

Catalog No. :
ACJHSU719
CAS No. :
946386-09-0
Molecular Formula :
C16H25N3O2
Molecular Weight :
291.39

IUPAC Name:tert-butyl 4-(3-methylpyridin-2-yl)-1,4-diazepane-1-carboxylate

4-(3-Methyl-pyridin-2-yl)-[1,4]diazepane-1-carboxylic acid tert-butyl ester structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(3-Methyl-pyridin-2-yl)-[1,4]diazepane-1-carboxylic acid tert-butyl ester
IUPAC Nametert-butyl 4-(3-methylpyridin-2-yl)-1,4-diazepane-1-carboxylate
MDL No.MFCD09749671
Molecular FormulaC16H25N3O2
Molecular Weight291.39
SMILESO=C(N1CCN(C2=NC=CC=C2C)CCC1)OC(C)(C)C
InChI KeyQHKLWSXPWFRVRQ-UHFFFAOYSA-N
Synonymtert-butyl 4-(3-methylpyridin-2-yl)-1,4-diazepane-1-carboxylate;1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-(3-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester
CAS No.946386-09-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACJHSU719 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRUCL427 route compound structure diagram
    ACRUCL427112275-50-0 In Stock
  2. Plus
  3. ACVODE062 route compound structure diagram
    ACVODE0623430-17-9 In Stock
  4. Then
  5. ACJHSU719 route product structure diagram
    ACJHSU719946386-09-0
Inquiry

2. ACJHSU719 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRUCL427 route compound structure diagram
    ACRUCL427112275-50-0 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJHSU719 route product structure diagram
    ACJHSU719946386-09-0
Inquiry

Comments (0)